Atossa Therapeutics Inc Reports Q4 EPS of -$0. …

🗝️ Key Points

• On March 25, 2025, Atossa Therapeutics Inc (ATOS, Financial) released its 8-K filing detailing the financial results for the year ending December 31, 2024.
• Atossa Therapeutics Inc, a clinical-stage biopharmaceutical company, is dedicated to developing innovative medicines for oncology, focusing on breast cancer and COVID-19.
• The company's lead product, (Z)-endoxifen, is Under development for breast cancer, while AT-H201 and AT-301 are being developed for COVID-19.Performance and Challenges Atossa.

On March 25, 2025, Atossa Therapeutics Inc (ATOS, Financial) released its 8-K filing detailing the financial results for the year ending December 31, 2024. Atossa Therapeutics Inc, a clinical-stage biopharmaceutical company, is dedicated to developing innovative medicines for oncology, focusing on breast cancer and COVID-19 treatments. The company’s lead product, (Z)-endoxifen, is under development for breast cancer, while AT-H201 and AT-301 are being developed for COVID-19.

Performance and Challenges

Atossa Therapeutics Inc reported a decrease in total operating expenses to $27.6 million for 2024, down from $31.4 million in 2023. This reduction is primarily attributed to decreased spending on clinical and pre-clinical trials, particularly for (Z)-endoxifen, and a reduction in compensation expenses. Despite these cost-saving measures, the company faces challenges in advancing its drug candidates through clinical trials and obtaining regulatory approvals, which are critical for its long-term success.

Financial Achievements

Atossa ended 2024 with $71.1 million in cash and cash equivalents and no debt, providing a solid financial foundation to support ongoing research and development activities. This financial stability is crucial for a biotechnology company like Atossa, which requires significant investment in clinical trials and regulatory processes to bring new therapies to market.

Income Statement and Key Metrics

The company’s research and development (R&D) expenses decreased by 19% to $14.1 million in 2024, driven by lower costs in clinical and pre-clinical trials and reduced stock-based compensation. General and administrative (G&A) expenses also saw a slight decline to $13.5 million, with notable reductions in compensation costs offset by increased professional fees and Legal expenses.

Strategic Developments

Atossa has strategically decided to focus on metastatic breast cancer, advancing (Z)-endoxifen for this indication. This decision is based on the potential for a more streamlined regulatory pathway and the urgent need for improved therapies in this area. The company also presented promising data from its Phase 2 EVANGELINE and KARISMA-Endoxifen trials, highlighting the efficacy and tolerability of (Z)-endoxifen.

“Metastatic breast cancer remains an area of critical unmet need, where improved therapies are urgently required,” said Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa.

Analysis and Outlook

Atossa Therapeutics Inc’s financial results and strategic focus on metastatic breast cancer position the company to potentially address significant unmet medical needs. The reduction in operating expenses and strong cash position provide a solid foundation for continued development of its promising drug candidates. However, the company must navigate the challenges of clinical trials and regulatory approvals to achieve its goals and deliver value to shareholders.

Explore the complete 8-K earnings release (here) from Atossa Therapeutics Inc for further details.

MORE IN INSIDE INVESTMENT NEWS

Here are 3 forces that drove a remarkable, record-setting week on Wall Street

Published: Saturday, April 18, 2026 · 2:13 PM

World’s biggest chocolate maker issues profit warning as cocoa prices collapse; shares plunge 17%

Published: Thursday, April 16, 2026 · 1:49 PM